Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.14
NAS:SPNC's Cash-to-Debt is ranked lower than
88% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. NAS:SPNC: 0.14 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SPNC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 113.56 Max: No Debt
Current: 0.14
Equity-to-Asset 0.15
NAS:SPNC's Equity-to-Asset is ranked lower than
91% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NAS:SPNC: 0.15 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SPNC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.15  Med: 0.76 Max: 0.94
Current: 0.15
0.15
0.94
Piotroski F-Score: 3
Altman Z-Score: 1.54
Beneish M-Score: -2.88
WACC vs ROIC
9.15%
-13.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -16.10
NAS:SPNC's Operating Margin % is ranked lower than
65% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. NAS:SPNC: -16.10 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SPNC' s Operating Margin % Range Over the Past 10 Years
Min: -20.54  Med: -6.01 Max: 2.1
Current: -16.1
-20.54
2.1
Net Margin % -21.38
NAS:SPNC's Net Margin % is ranked lower than
67% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. NAS:SPNC: -21.38 )
Ranked among companies with meaningful Net Margin % only.
NAS:SPNC' s Net Margin % Range Over the Past 10 Years
Min: -24.18  Med: -7.44 Max: 8.72
Current: -21.38
-24.18
8.72
ROE % -71.87
NAS:SPNC's ROE % is ranked lower than
81% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. NAS:SPNC: -71.87 )
Ranked among companies with meaningful ROE % only.
NAS:SPNC' s ROE % Range Over the Past 10 Years
Min: -60.77  Med: -9.77 Max: 8.5
Current: -71.87
-60.77
8.5
ROA % -13.69
NAS:SPNC's ROA % is ranked lower than
61% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. NAS:SPNC: -13.69 )
Ranked among companies with meaningful ROA % only.
NAS:SPNC' s ROA % Range Over the Past 10 Years
Min: -13.44  Med: -7.9 Max: 7.25
Current: -13.69
-13.44
7.25
ROC (Joel Greenblatt) % -55.45
NAS:SPNC's ROC (Joel Greenblatt) % is ranked lower than
64% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. NAS:SPNC: -55.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SPNC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -69.69  Med: -16.46 Max: 8.69
Current: -55.45
-69.69
8.69
3-Year Revenue Growth Rate 15.70
NAS:SPNC's 3-Year Revenue Growth Rate is ranked higher than
82% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. NAS:SPNC: 15.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SPNC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6  Med: 7.35 Max: 32.3
Current: 15.7
-6
32.3
3-Year EPS without NRI Growth Rate 413.00
NAS:SPNC's 3-Year EPS without NRI Growth Rate is ranked higher than
100% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. NAS:SPNC: 413.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SPNC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -70.5  Med: 10.05 Max: 413
Current: 413
-70.5
413
GuruFocus has detected 7 Warning Signs with The Spectranetics Corp $NAS:SPNC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SPNC's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

SPNC Guru Trades in Q2 2016

Steven Cohen 276,800 sh (New)
Ron Baron 1,772,488 sh (unchged)
» More
Q3 2016

SPNC Guru Trades in Q3 2016

Paul Tudor Jones 14,550 sh (New)
Jim Simons 32,222 sh (New)
Ron Baron 1,528,500 sh (-13.77%)
Steven Cohen 129,900 sh (-53.07%)
» More
Q4 2016

SPNC Guru Trades in Q4 2016

John Hussman 140,000 sh (New)
Ron Baron 1,540,500 sh (+0.79%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 24,900 sh (-80.83%)
» More
Q1 2017

SPNC Guru Trades in Q1 2017

Jim Simons 61,922 sh (New)
Steven Cohen 205,667 sh (+725.97%)
John Hussman Sold Out
Ron Baron 1,301,500 sh (-15.51%)
» More
» Details

Insider Trades

Latest Guru Trades with SPNC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:BABY, NYSE:ITGR, OTCPK:NMRD, NAS:CSII, OTCPK:MZRTF, NAS:VASC, NAS:KTWO, NAS:CNMD, NAS:MDXG, NAS:OFIX, NAS:CYNO, NAS:XENT, OTCPK:CSRMY, OTCPK:IOBCF, NAS:GNMK, NYSE:CRY, NAS:INGN, NAS:AXGN, OTCPK:NHNKY, NYSE:IVC » details
Traded in other countries:SC7.Germany,
Headquarter Location:USA
The Spectranetics Corp develops, manufactures, markets and distributes single-use medical devices. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart and to remove pacemaker and defibrillator cardiac leads.

Spectranetics manufactures and sells single-use medical devices used in minimally invasive cardiovascular procedures. The firm operates in the three categories: vascular intervention, lead management, and laser, service, and other. The vascular intervention business contributes the majority of revenue and sells laser and aspiration catheters, balloon catheters, and support catheters. The lead management business sells devices used to remove pacemaker and defibrillator cardiac leads. The laser, service, and other business includes a laser system for cardiovascular procedures. Spectranetics generates the vast majority of its revenue in the United States.

Guru Investment Theses on The Spectranetics Corp

Baron Funds Comments on The Spectranetics Corp. - Aug 19, 2015

The Spectranetics Corporation (NASDAQ:SPNC) is a medical device company that specializes in equipment that clears plaque from cardiac and peripheral (arm and leg) arteries. Shares fell after the company reported that it had missed revenues in the first quarter and lowered full year guidance. We believe the market misunderstood certain dynamics and bought more near the bottom. (Randy Gwirtzman)





From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
PB Ratio 19.41
SPNC's PB Ratio is ranked lower than
96% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. SPNC: 19.41 )
Ranked among companies with meaningful PB Ratio only.
SPNC' s PB Ratio Range Over the Past 10 Years
Min: 0.78  Med: 4.41 Max: 21.09
Current: 19.41
0.78
21.09
PS Ratio 4.16
SPNC's PS Ratio is ranked lower than
65% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. SPNC: 4.16 )
Ranked among companies with meaningful PS Ratio only.
SPNC' s PS Ratio Range Over the Past 10 Years
Min: 0.69  Med: 3.56 Max: 7.92
Current: 4.16
0.69
7.92
EV-to-EBIT -31.91
SPNC's EV-to-EBIT is ranked lower than
99.99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. SPNC: -31.91 )
Ranked among companies with meaningful EV-to-EBIT only.
SPNC' s EV-to-EBIT Range Over the Past 10 Years
Min: -4632.7  Med: -15.7 Max: 2801.8
Current: -31.91
-4632.7
2801.8
EV-to-EBITDA -80.96
SPNC's EV-to-EBITDA is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. SPNC: -80.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
SPNC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -371.8  Med: 24.1 Max: 9534.2
Current: -80.96
-371.8
9534.2
Current Ratio 1.87
SPNC's Current Ratio is ranked lower than
60% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. SPNC: 1.87 )
Ranked among companies with meaningful Current Ratio only.
SPNC' s Current Ratio Range Over the Past 10 Years
Min: 1.4  Med: 2.7 Max: 17.73
Current: 1.87
1.4
17.73
Quick Ratio 1.43
SPNC's Quick Ratio is ranked lower than
55% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. SPNC: 1.43 )
Ranked among companies with meaningful Quick Ratio only.
SPNC' s Quick Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.35 Max: 16.5
Current: 1.43
1.2
16.5
Days Inventory 140.39
SPNC's Days Inventory is ranked lower than
55% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. SPNC: 140.39 )
Ranked among companies with meaningful Days Inventory only.
SPNC' s Days Inventory Range Over the Past 10 Years
Min: 82.8  Med: 89.76 Max: 146.27
Current: 140.39
82.8
146.27
Days Sales Outstanding 57.68
SPNC's Days Sales Outstanding is ranked higher than
65% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. SPNC: 57.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPNC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.49  Med: 56.65 Max: 73.19
Current: 57.68
48.49
73.19
Days Payable 34.44
SPNC's Days Payable is ranked lower than
76% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. SPNC: 34.44 )
Ranked among companies with meaningful Days Payable only.
SPNC' s Days Payable Range Over the Past 10 Years
Min: 14.31  Med: 21.02 Max: 33.28
Current: 34.44
14.31
33.28

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.60
SPNC's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. SPNC: -1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SPNC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -40.2  Med: -6.9 Max: -0.8
Current: -1.6
-40.2
-0.8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.17
SPNC's Price-to-Median-PS-Value is ranked lower than
69% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. SPNC: 1.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SPNC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 1 Max: 5.23
Current: 1.17
0.18
5.23
Earnings Yield (Greenblatt) % -3.13
SPNC's Earnings Yield (Greenblatt) % is ranked lower than
66% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. SPNC: -3.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SPNC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 0.7 Max: 31.1
Current: -3.13
0.1
31.1

More Statistics

Revenue (TTM) (Mil) $277.6
EPS (TTM) $ -1.38
Beta1.36
Short Percentage of Float11.83%
52-Week Range $16.83 - 30.15
Shares Outstanding (Mil)43.77

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 302 367 462
EPS ($) -1.09 -0.71 -0.13
EPS without NRI ($) -1.09 -0.71 -0.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SPNC

Headlines

Articles On GuruFocus.com
Healthcare Veteran John Fletcher Joins MRI Interventions’ Board of Directors May 11 2017 
Spectranetics Announces First Quarter 2017 Conference Call Apr 07 2017 
Steven Cohen's Point72 Raises Stake in Spectranetics Oct 22 2015 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of The Spectranetics Corporation of P Sep 08 2015 
Baron Funds Comments on The Spectranetics Corp. Aug 19 2015 
Baron Funds Comments on Spectranetics Corporation Feb 26 2014 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 08 2010 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 06 2009 
Spectranetics Corp. Reports Operating Results (10-Q) Aug 10 2009 
Spectranetics Corp. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
ETFs with exposure to The Spectranetics Corp. : May 22, 2017 May 22 2017
The Spectranetics Corp. breached its 50 day moving average in a Bearish Manner : SPNC-US : May 15,... May 15 2017
Healthcare Veteran John Fletcher Joins MRI Interventions’ Board of Directors May 11 2017
Edited Transcript of SPNC earnings conference call or presentation 27-Apr-17 8:30pm GMT May 04 2017
The Spectranetics Corp. :SPNC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 1, 2017 May 01 2017
Spectranetics reports 1Q loss Apr 27 2017
Spectranetics Reports First Quarter 2017 Revenue of $69.7 million Apr 27 2017
The Spectranetics Corp. – Value Analysis (NASDAQ:SPNC) : April 20, 2017 Apr 20 2017
The Spectranetics Corp. breached its 50 day moving average in a Bearish Manner : SPNC-US : April 19,... Apr 19 2017
ETFs with exposure to The Spectranetics Corp. : April 17, 2017 Apr 17 2017
Spectranetics Announces First Quarter 2017 Conference Call Apr 07 2017
The Spectranetics Corp. :SPNC-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017 Mar 02 2017
Edited Transcript of SPNC earnings conference call or presentation 23-Feb-17 9:30pm GMT Feb 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)